Pleckstrin homology-like domain, family A, member 1 (PHLDA1) and cancer

Imagem de Miniatura
Arquivos
art_NAGAI_Pleckstrin_homologylike_domain_family_A_member_1_PHLDA1_2016.PDF (879.78 KB)
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
Citação
BIOMEDICAL REPORTS, v.4, n.3, p.275-281, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Pleckstrin homology-like domain, family A, member 1 (PHLDA1) encodes a member of an evolutionarily conserved pleckstrin homology-related domain protein family. It was first identified as a potential transcription factor required for Fas expression and activation-induced apoptosis in mouse T cell hybridomas. The exact molecular and biological functions of PHLDA1 remain to be elucidated. However, its expression is induced by a variety of external stimuli and there is evidence that it may function as a transcriptional activator that acts as a mediator of apoptosis, proliferation, differentiation and cell migration dependent on the cellular type and context. Recently, PHLDA1 has received attention due to its association with cancer. In the present review, the current knowledge of PHLDA1 protein structure, expression regulation and function is summarized. In addition, the current data in the literature is reviewed with regards to the role of PHLDA1 in cancer pathogenesis.
Palavras-chave
PHLDA1, pleckstrin homology-like, cancer, tumor suppressor gene, oncogene, downregulation, stem cell
URI
https://observatorio.fm.usp.br/handle/OPI/13903
Referências
  1. Frank D, 1999, MAMM GENOME, V10, P1150, DOI 10.1007/s003359901182
  2. Gomes I, 1999, J NEUROCHEM, V73, P612, DOI 10.1046/j.1471-4159.1999.0730612.x
  3. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  4. Hinz T, 2001, CELL SIGNAL, V13, P345, DOI 10.1016/S0898-6568(01)00141-3
  5. Butland SL, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-126
  6. Carlisle RE, 2012, AM J PHYSIOL-RENAL, V303, pF467, DOI 10.1152/ajprenal.00481.2011
  7. Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001
  8. Coutinho-Camillo CM, 2013, VIRCHOWS ARCH, V463, P31, DOI 10.1007/s00428-013-1438-9
  9. Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
  10. Wu SF, 2010, J CLIN ENDOCR METAB, V95, P1220, DOI 10.1210/jc.2009-1662
  11. Liu F, 2011, MOL REPROD DEV, V78, P283, DOI 10.1002/mrd.21304
  12. WILLIAMSON MP, 1994, BIOCHEM J, V297, P249
  13. Sellheyer K, 2011, BRIT J DERMATOL, V164, P141, DOI 10.1111/j.1365-2133.2010.10045.x
  14. Oberg HH, 2004, CELL DEATH DIFFER, V11, P674, DOI 10.1038/sj.cdd.4401407
  15. Moad AIH, 2013, CELL BIOCHEM BIOPHYS, V66, P567, DOI 10.1007/s12013-012-9504-5
  16. Kuske MDA, 2000, CYTOGENET CELL GENET, V89, P1, DOI 10.1159/000015575
  17. Wang RX, 1998, J IMMUNOL, V161, P2201
  18. Nagai MA, 2007, BREAST CANCER RES TR, V106, P49, DOI 10.1007/s10549-006-9475-6
  19. Shang YL, 2013, CURR CANCER DRUG TAR, V13, P915
  20. Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001
  21. Pasquier J, 2015, J ONCOL, DOI 10.1155/2015/792182
  22. Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200
  23. Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4
  24. Guezguez A, 2014, EXP CELL RES, V322, P355, DOI 10.1016/j.yexcr.2014.02.009
  25. Kastrati I, 2015, ONCOGENE, V34, P2309, DOI 10.1038/onc.2014.180
  26. Scheffzek K, 2012, FEBS LETT, V586, P2662, DOI 10.1016/j.febslet.2012.06.006
  27. Sohn EJ, 2010, CANCER RES, V70, P1154, DOI 10.1158/0008-5472.CAN-09-1993
  28. Neef R, 2002, CANCER RES, V62, P5920
  29. Xu Q, 2010, J MOL BIOL, V396, P31, DOI 10.1016/j.jmb.2009.11.006
  30. Joo JH, 2007, CANCER RES, V67, P7929, DOI 10.1158/0008-5472.CAN-07-0931
  31. Ren L, 2015, ONCOTARGET, V6, P29469, DOI 10.18632/oncotarget.5177
  32. Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468
  33. Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
  34. Zhao P, 2015, INT J CLIN EXP PATHO, V8, P5230
  35. Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7
  36. Johnson EO, 2011, J CELL SCI, V124, P2711, DOI 10.1242/jcs.084970
  37. Chiu ST, 2005, CANCER EPIDEM BIOMAR, V14, P437, DOI 10.1158/1055-9965.EPI-04-0396
  38. Marchiori AC, 2008, BRAZ J MED BIOL RES, V41, P579, DOI 10.1590/S0100-879X2008005000029
  39. Boro A, 2012, INT J CANCER, V131, P2153, DOI 10.1002/ijc.27472
  40. Hayashida N, 2006, EMBO J, V25, P4773, DOI 10.1038/sj.emboj.7601370
  41. Toyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200
  42. Liu CR, 2015, J NEUROGENET, V29, P41, DOI 10.3109/01677063.2015.1073275
  43. Li GY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106349
  44. Murata T, 2014, EXP CELL RES, V320, P247, DOI 10.1016/j.yexcr.2013.10.023
  45. Oberst MD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-189
  46. Sakthianandeswaren A, 2011, CANCER RES, V71, P3709, DOI 10.1158/0008-5472.CAN-10-2342

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03